Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × belzutifan × Clear all

Status

Active not recruiting 15 Recruiting 10 Not yet recruiting 2 Withdrawn 1 Completed 1

Sponsor Class

Study Type

Observational 1

Sponsor

Conditions

von Hippel-Lindau Disease 1

Interventions

Radiotherapy 106 Cyclophosphamide 106 Cisplatin 102 pembrolizumab 97 Paclitaxel 83 Carboplatin 83 Gemcitabine 76 Nivolumab 69 Magnetic Resonance Spectroscopy 69 Fluorouracil 64 Dexamethasone 60 Bevacizumab 59 Radiosurgery 56 Docetaxel 56 Rituximab 50 Oxaliplatin 48 Leucovorin 48 Capecitabine 47 Biopsy 47 fludarabine 45 Doxorubicin 42 durvalumab 40 Drug Therapy 39 Pemetrexed 37 fludarabine phosphate 36 Etoposide 36 Cytarabine 35 Radiation 33 Lenalidomide 32 Specimen Handling 31

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06554730 2024-11-29

MK-6482-026

Merck Sharp & Dohme LLC

von Hippel-Lindau Disease

Data powered by HemOnc (CC BY 4.0) Colophon ⚡